cMET Cancer Research Results

cMET, cellular hepatocyte growth factor receptor: Click to Expand ⟱
Source:
Type:
c-MET, also known as the hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that plays a crucial role in various cellular processes, including cell proliferation, survival, migration, and differentiation. It is activated by its ligand, hepatocyte growth factor (HGF). Dysregulation of the c-MET signaling pathway has been implicated in several types of cancer.

c-Met is often overexpressed or mutated in cancer and is associated with poor prognosis, increased metastasis, and resistance to therapies.
Scientific Papers found: Click to Expand⟱
308- Api,    Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling
- in-vitro, GBM, U87MG - in-vitro, GBM, U373MG
cMET↓, Akt↓, Nanog↓, SOX2↓,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, VEGFR2/KDR/Flk1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27/CDKN1B↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
3156- Ash,    Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug
- Review, Var, NA
MAPK↑, p38↑, BAX↑, BIM↑, CHOP/DDIT3↑, ROS↑, DR5↑, Apoptosis↑, Ferroptosis↑, GPx4↓, BioAv↝, HSP90↓, RET↓, E6↓, E7↓, Akt↓, cMET↓, Glycolysis↓, TCA↓, NOTCH1↓, STAT3↓, AP-1↓, PI3K↓, eIF2α↓, HO-1↑, TumCCA↑, CDK1↓, *hepatoP↑, *GSH↑, *NRF2↑, Wnt↓, EMT↓, uPA↓, CSCs↓, Nanog↓, SOX2↓, CD44↓, lactateProd↓, Iron↑, NF-kB↓,
473- CUR,    Curcumin inhibits epithelial-mesenchymal transition in oral cancer cells via c-Met blockade
- in-vitro, Oral, HSC4 - in-vitro, Oral, Ca9-22
Vim↓, p‑cMET↓, p‑ERK↓, pro‑MMP9↓, E-cadherin↑,
1443- Deg,    Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-435 - in-vitro, BC, BT549
EGFR↓, Akt↓, p‑ERK↓, NF-kB↓, p‑STAT3↓, survivin↓, Myc↓, TumCG↓, cMET↓,
1446- Deg,    Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells
- in-vitro, BC, 4T1
cMET↓, p‑ERK↓, p‑Akt↓, TumCMig↓, TumCG↓, Weight∅, *toxicity∅, Hif1a↓, TumMeta↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp/ABCB1↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP/DDIT3↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2/PTGS2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
8235- LCA,    Anticancer effects of licochalcones: A review of the mechanisms
- Review, Var, NA
mt-Apoptosis↑, TumAuto↑, TumCMig↓, LC3‑Ⅱ/LC3‑Ⅰ↑, ATG5↑, ATG7↑, p62↑, CHOP/DDIT3↑, ER Stress↑, UPR↑, ATG3↑, Beclin-1/ATG6↑, ATG16L1↑, PERK↑, ATF4↑, ATP↓, Hif1a↓, GLUT1↓, PDK1 / PDPK1↓, Bcl-xL↓, Bcl-2↓, BAD↑, BAX↑, Casp3↑, survivin↓, EGFR↓, ERK↓, Akt↓, mtDam↑, MMP↓, Cyt‑c↑, Casp↑, MDM2↓, CycB/CCNB1↓, CDC2↓, CDC25↓, TumCCA↑, TumCP↓, Wnt↓, β-catenin/ZEB1↓, Sp1/3/4↓, MMP-10↓, MMP3↓, TumCI↓, Imm↑, PD-L1↓, ROS↑, 4E-BP1↓, eIF2α↓, PI3K↓, mTOR↓, p‑cMET↑, Ca+2↑, RUBCN↓, ATG13↑, TSC1↑, TSC2↑, PRAS40↑, PP2A↑, ULK1/ATG1↑, THEM4/CTMP↑, DR5↑, Fas↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, PKCδ↓, P70S6K↓, VEGF↓, angioG↓, HK2↓, Glycolysis↓, TrxR1↓, APAF1↑, cl‑PARP↑, Bax:Bcl2↑, ABCG2↓, BioEnh↑,
1200- LT,    Inhibition of Fatty Acid Synthase by Luteolin Post-Transcriptionally Downregulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation
- in-vitro, Pca, DU145
FASN↓, cMET↓, HGF/c-Met↓,
4646- OLEC,    Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology
- Review, Var, NA
BioAv↓, *Inflam↓, *antiOx↓, cMET↓, STAT3↓, TNF-α↓, COX2/PTGS2↓, EMT↓, angioG↓, *GutMicro↝, eff↑,
2995- PL,    Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover
- in-vitro, Lung, H1975 - in-vitro, Lung, PC9 - in-vivo, NA, NA
Sp1/3/4↓, cMET↓, Apoptosis↑, Cyt‑c↑, p‑ERK↓, p‑Akt↓, TumCG↓,
2940- PL,    Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors
- in-vitro, PC, PANC1 - in-vitro, Lung, A549 - in-vitro, Kidney, 786-O - in-vitro, BC, SkBr3
ROS↑, TumCP↓, Apoptosis↑, eff↓, Sp1/3/4↓, cycD1/CCND1↓, survivin↓, cMyc↓, EGFR↓, cMET↓,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP/DDIT3↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
89- QC,  doxoR,    Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met
- in-vitro, Pca, PC3
PI3K/Akt↓, cMET↓, Casp3↑, Casp9↑, MMP↓, ChemoSen↑, ROS↑,
7951- RT,  BuckWS,    The anticancer potential of the dietary polyphenol rutin: Current status, challenges, and perspectives
- Review, Nor, NA
*Dose↝, *BioAv↓, *BioAv↓, *BioAv↓, *BioAv↓, *BioAv↝, TumCP↓, Risk↓, *radioP↑, chemoPv↑, TumCCA↑, GSK‐3β↑, Wnt↓, β-catenin/ZEB1↓, ROS↑, BAX↑, Casp3↑, Casp8↑, Casp9↑, PARP↑, Beclin-1/ATG6↑, ATG5↑, LC3II↑, DNMT1↓, P21↑, CDK1↑, CycB/CCNB1↓, TNF-α↑, VEGF↓, IL1β↓, NF-kB↓, AP-1↓, MYCN↓, AMPK↑, MAPK↓, PI3K↓, Akt↓, cMET↓, P-gp/ABCB1↓, MRP1/ABCC1↓, ABCG2↓, MMPs↓, TNF-α↓, iNOS↓, COX2/PTGS2↓, angioG↓, STAT3↓, *chemoP↑, *ROS↓, *MDA↓, *P53↓, *Casp3↓, *Casp9↓, *JNK↓, *TNF-α↓, *p38↓, *MAPK↓, GSH↓, ChemoSen↑, *hepatoP↑, *COX1↓, *COX2/PTGS2↓, *15-LOX/ALOX15↓, RenoP↑, *toxicity↓,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1/ATG6↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2/PTGS2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2/KDR/Flk1↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27/CDKN1B↑, P21↑, ChemoSen↑,

Showing Research Papers: 1 to 16 of 16

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 16

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ATG13↑, 1,   ATG16L1↑, 1,   MYCN↓, 1,   RUBCN↓, 1,   THEM4/CTMP↑, 1,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1,   ULK1/ATG1↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Ferroptosis↑, 2,   GPx4↓, 1,   GSH↓, 2,   HO-1↑, 2,   Iron↑, 1,   MDA↑, 1,   NQO1↑, 1,   NRF2↑, 1,   ROS↑, 6,   ROS⇅, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,   TrxR↓, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   CDC2↓, 2,   CDC25↓, 2,   MMP↓, 2,   mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 2,   ATG7↑, 2,   cMyc↓, 3,   FASN↓, 1,   Glycolysis↓, 3,   HK2↓, 2,   lactateProd↓, 1,   PDK1 / PDPK1↓, 1,   PI3K/Akt↓, 1,   PPARγ↑, 1,   TCA↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 9,   p‑Akt↓, 2,   APAF1↑, 1,   Apoptosis↑, 5,   mt-Apoptosis↑, 1,   BAD↑, 1,   BAX↑, 5,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Bcl-xL↓, 1,   BID↓, 1,   BIM↑, 2,   Casp↑, 1,   Casp3↑, 5,   Casp7↑, 1,   Casp8↑, 3,   Casp9↑, 3,   cl‑Casp9↑, 1,   cFLIP↓, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 2,   DR5↑, 3,   Fas↑, 2,   Ferroptosis↑, 2,   HGF/c-Met↓, 1,   iNOS↓, 2,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 2,   Mcl-1↓, 1,   MDM2↓, 2,   Myc↓, 2,   oncosis↑, 1,   p27/CDKN1B↑, 2,   p38↑, 2,   survivin↓, 6,   TRAIL↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑HER2/EBBR2↓, 1,   RET↓, 1,   Sp1/3/4↓, 5,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 4,   eIF2α↓, 3,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 1,   HSP90↓, 1,   PERK↑, 1,   p‑PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG3↑, 1,   ATG5↑, 2,   Beclin-1/ATG6↑, 3,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↑, 2,   p62↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   CYP1B1↑, 1,   DNAdam↑, 1,   DNMT1↓, 2,   HR↓, 1,   p16↑, 2,   P53↑, 2,   PARP↑, 1,   cl‑PARP↑, 1,   PCNA↓, 1,   RAD51↓, 1,   UHRF1↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK1↑, 1,   CDK2↓, 2,   CDK4↓, 2,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 4,   cycE1↓, 1,   E2Fs↓, 1,   P21↑, 3,   RB1↓, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   CD133↓, 1,   CD44↓, 1,   cFos↓, 1,   cMET↓, 13,   p‑cMET↓, 1,   p‑cMET↑, 2,   CSCs↓, 1,   EMT↓, 3,   ERK↓, 5,   p‑ERK↓, 4,   FOXO↑, 1,   p‑FOXO3↓, 1,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   HDAC↓, 1,   HDAC1↓, 1,   mTOR↓, 5,   Nanog↓, 3,   Nestin↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   OCT4↓, 1,   P70S6K↓, 2,   PI3K↓, 5,   RAS↑, 1,   Shh↓, 1,   SOX2↓, 3,   STAT3↓, 5,   p‑STAT3↓, 2,   TOP2↓, 1,   TumCG↓, 4,   Wnt↓, 4,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   AP-1↓, 3,   Ca+2↑, 1,   CDK4/6↓, 1,   DLC1↑, 1,   E-cadherin↑, 2,   ITGA5↓, 1,   ITGB1↑, 1,   Ki-67↓, 1,   MMP-10↓, 1,   MMP2↓, 2,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 2,   pro‑MMP9↓, 1,   MMPs↓, 2,   N-cadherin↓, 2,   NCAM↑, 1,   PKCδ↓, 1,   Slug↓, 2,   Snail↓, 2,   TGF-β↓, 1,   TIMP2↑, 1,   TSC1↑, 1,   TumCI↓, 3,   TumCMig↓, 3,   TumCP↓, 4,   TumMeta↓, 2,   Twist↓, 3,   uPA↓, 1,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 4,   ATF4↑, 2,   EGFR↓, 6,   Hif1a↓, 3,   NO↓, 1,   VEGF↓, 5,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 3,   CXCL1↓, 1,   CXCR4↓, 2,   IKKα↓, 1,   IL1↓, 2,   IL10↓, 1,   IL12↓, 1,   IL1β↓, 1,   IL2↑, 1,   IL6↓, 3,   IL8↓, 1,   Imm↑, 1,   JAK1↓, 1,   JAK2↓, 2,   MIP2↓, 1,   NF-kB↓, 7,   p65↓, 1,   PD-L1↓, 1,   PGE2↓, 1,   TNF-α↓, 4,   TNF-α↑, 1,  

Protein Aggregation(tgid=19) ⓘ

PP2A↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 2,   BioAv↓, 1,   BioAv↝, 1,   BioEnh↑, 1,   ChemoSen↑, 4,   eff↓, 1,   eff↑, 1,   MRP1/ABCC1↓, 1,   RadioS↑, 1,   TET2↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BMPs↑, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 6,   p‑HER2/EBBR2↓, 1,   IL6↓, 3,   Ki-67↓, 1,   Myc↓, 2,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 1,   PRAS40↑, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 1,   TumW↓, 1,   Weight∅, 1,  
Total Targets: 251

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

15-LOX/ALOX15↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 1,   Catalase↑, 1,   GSH↑, 3,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 2,   ROS↓, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   NADPH↓, 1,  

Cell Death(tgid=5) ⓘ

Casp3↓, 2,   Casp9↓, 1,   JNK↓, 1,   MAPK↓, 1,   p38↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↓, 1,  

Migration(tgid=13) ⓘ

p‑Rac1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 1,   COX2/PTGS2↓, 2,   IKKα↑, 1,   IL10↓, 1,   IL6↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↝, 1,   Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   GutMicro↝, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   chemoP↑, 1,   hepatoP↑, 4,   neuroP↑, 1,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 45

Scientific Paper Hit Count for: cMET, cellular hepatocyte growth factor receptor
3 Piperlongumine
2 Deguelin
1 Apigenin (mainly Parsley)
1 Artemisinin
1 Ashwagandha(Withaferin A)
1 Curcumin
1 Honokiol
1 Licochalcone A
1 Luteolin
1 Oleocanthal
1 Quercetin
1 doxorubicin
1 Rutin
1 buckwheat sprouts
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:484  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page